Financhill
Sell
20

ATRA Quote, Financials, Valuation and Earnings

Last price:
$6.91
Seasonality move :
-15.4%
Day range:
$7.17 - $7.60
52-week range:
$5.40 - $20.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.42x
P/B ratio:
--
Volume:
49.9K
Avg. volume:
87.8K
1-year change:
-53.8%
Market cap:
$42M
Revenue:
$128.9M
EPS (TTM):
-$12.97

Earnings Data

Next earnings date for ATRA
May 09
2025
Most recent earnings per share
-$1.19
Beat by $2.30
(Mar 7/2025)
Consensus Estimate
-$3.49
(Mar 7/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

ATRA Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
05/09/2025 Q1 $3.4M -- -- -$2.19 --
03/07/2025 Q4 $16.6M $32.8M -$1.19 -$3.49 $2.30
11/12/2024 Q3 $35.2M $40.2M -$2.93 -$3.50 $0.57
08/12/2024 Q2 $37.1M $28.6M -$3.10 -$2.24 -$0.86
05/09/2024 Q1 $24.7M $27.4M -$5.75 -$6.42 $0.67
03/28/2024 Q4 $14.3M $4.3M -$13.98 -$12.05 -$1.93
11/01/2023 Q3 $1.3M $2.1M -$16.40 -$16.40 --
08/08/2023 Q2 $3.8M $957K -$16.91 -$16.51 -$0.40
05/08/2023 Q1 $30.7M $1.2M -$18.00 -$9.51 -$8.49
02/08/2023 Q4 $39.7M $221K -$18.00 -$9.70 -$8.30
11/08/2022 Q3 $3.7M $4.5M -$20.50 -$19.34 -$1.16
08/08/2022 Q2 -- $51.6M $4.50 -- --
05/05/2022 Q1 -- $7.3M -$21.75 -- --
02/28/2022 Q4 -- $7.5M -$24.00 -- --
11/04/2021 Q3 -- $5.4M -$22.50 -- --
08/09/2021 Q2 -- $3.9M -$22.75 -- --
05/04/2021 Q1 -- $3.6M -$21.50 -- --
03/01/2021 Q4 -- -- -$23.75 -- --
11/09/2020 Q3 -- -- -$23.00 -- --
08/05/2020 Q2 -- -- -$28.50 -- --
05/06/2020 Q1 -- -- -$30.00 -- --
02/27/2020 Q4 -- -- -$34.00 -- --
11/07/2019 Q3 -- -- -$32.75 -- --
08/08/2019 Q2 -- -- -$40.00 -- --
05/09/2019 Q1 -- -- -$36.00 -- --
02/26/2019 Q4 -- -- -$43.75 -- --
11/06/2018 Q3 -- -- -$32.25 -- --
08/01/2018 Q2 -- -- -$28.75 -- --
05/08/2018 Q1 -- -- -$26.25 -- --
02/27/2018 Q4 -- -- -$28.75 -- --
11/09/2017 Q3 -- -- -$25.50 -- --
08/07/2017 Q2 -- -- -$23.50 -- --
05/04/2017 Q1 -- -- -$22.00 -- --
03/09/2017 Q4 -- -- -$15.75 -- --
11/04/2016 Q3 -- -- -$22.00 -- --
08/08/2016 Q2 -- -- -$16.50 -- --
05/05/2016 Q1 -- -- -$14.50 -- --
03/03/2016 Q4 -- -- -$18.75 -- --
11/11/2015 Q3 -- -- -$10.75 -- --
08/06/2015 Q2 -- -- -$15.50 -- --
05/28/2015 Q1 -- -- -$10.50 -- --

Atara Biotherapeutics Earnings Questions

  • How Much did Atara Biotherapeutics Generate in Revenue Last Quarter?

    Atara Biotherapeutics reported $32.8M worth of top line sales in its most recent quarter.

  • Did Atara Biotherapeutics Beat Earnings Last Quarter?

    Atara Biotherapeutics announced earnings per share of -$1.19 which represents a beat of analyst forecast a -$3.49 per share.

  • Is Atara Biotherapeutics Profitable?

    Atara Biotherapeutics reported $26M that represents $2.42 per share over the last quarter.

  • What is the Analyst Consensus for Atara Biotherapeutics EPS Next Year?

    Atara Biotherapeutics's earnings are forecast to decrease from -$11.41 per share to -$4.24 per share next year representing a decrease of -48.79%.

  • When is Atara Biotherapeutics's Earnings Date?

    Atara Biotherapeutics's next earnings date is May 9, 2025.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock